Benitec Biopharma Inc. Common Stock (BNTC)
Stock · NASDAQ · Health Care
$8.11as of 10/16/2026
Price chart
Active signals
BNTC Signal Track Record
How signals performed across all stocks →What BNTC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | +1.8% | 53% | October 5, 2026 |
| Bollinger Band Breakout | 27 | -7.0% | 30% | August 7, 2026 |
| Bollinger Band Breakdown | 20 | +7.1% | 70% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -10.4% | 18% | August 31, 2026 |
| Any 20-session window (baseline) | 0.0% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BNTC
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a s…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 24
- Website
- benitec.com/
Fundamentals
- 1-day range
- $8.82$9.25
- Market cap
- $451.07M
- P/E (trailing)
- —
- P/E (forward)
- -0.96
- EPS (trailing)
- $-1.11
- Dividend yield
- —
- Beta
- 0.22
- Avg. volume
- 156.5K
- Dividend pay date
- November 18, 2019
How Benitec Biopharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2023 annual results
Source: 10-K filed Sep 21, 2023 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Benitec Biopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BNTCBenitec Biopharma Inc. Common Stock$8.11▼ 4.14%Market cap $451.07MP/E —$8.52$16.76
- RZLTRezolute Inc. Common Stock (NV)$3.58▼ 8.21%Market cap $452.57MP/E —$1.07$11.46
- PRTAProthena Corporation plc Ordinary Shares$8.35▼ 1.76%Market cap $449.19MP/E —$7.73$11.8
- LRMRLarimar Therapeutics Inc. Common Stock$1.99▼ 0.25%Market cap $436.31MP/E —$2.06$6.42
- ASMBAssembly Biosciences Inc. Common Stock$20.09▼ 2.33%Market cap $420.36MP/E 333.50$19.98$39.71
- EVMNEvommune Inc. Common Stock$5.17▼ 12.82%Market cap $481.93MP/E —$6.52$33.2
- QTTBQ32 Bio Inc. Common Stock$7.52▼ 3.22%Market cap $482.18MP/E 7.95$1.91$23.57
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BNTC Benitec Biopharma Inc. Common Stock | $451.07M | — | $8.11 | ▼ 4.14% | $8.52$16.76 |
| RZLT Rezolute Inc. Common Stock (NV) | $452.57M | — | $3.58 | ▼ 8.21% | $1.07$11.46 |
| PRTA Prothena Corporation plc Ordinary Shares | $449.19M | — | $8.35 | ▼ 1.76% | $7.73$11.8 |
| LRMR Larimar Therapeutics Inc. Common Stock | $436.31M | — | $1.99 | ▼ 0.25% | $2.06$6.42 |
| ASMB Assembly Biosciences Inc. Common Stock | $420.36M | 333.50 | $20.09 | ▼ 2.33% | $19.98$39.71 |
| EVMN Evommune Inc. Common Stock | $481.93M | — | $5.17 | ▼ 12.82% | $6.52$33.2 |
| QTTB Q32 Bio Inc. Common Stock | $482.18M | 7.95 | $7.52 | ▼ 3.22% | $1.91$23.57 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal StudyYahoo · 10/5/2026
- After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)Yahoo · 9/25/2026
- Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17Benzinga · 9/15/2026
- Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational UpdateYahoo · 9/14/2026
- Benitec Biopharma Q4 EPS $(0.26), InlineBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Friedman David Matthew · May 26, 2026 · Grant35.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 32.09M
- Total value held
- $341.84M
- Institutional holders
- 84
- Unknown11.55M
- Unknown2.88M
- Unknown2.38M
- Unknown2.12M
- Unknown1.85M
- Unknown1.44M
- Unknown1.19M
- Unknown931.6K
- Unknown923.0K
- Unknown750.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Benitec Biopharma shares fell 23.9% over four weeks
Benitec Biopharma's stock dropped 23.9% over the past four weeks, according to a recent Yahoo article. The piece outlines factors that could help the price recover, noting the low RSI of 26.9 and the stock's proximity to a well‑tested support level at $10.89. The company’s average analyst target is $24.33, well above its current range.
Benitec Biopharma shares fell 23.9% over four weeks. Benitec Biopharma's stock dropped 23.9% over the past four weeks, according to a recent Yahoo article. The piece outlines factors that could help the price recover, noting the low RSI of 26.9 and the stock's proximity to a well‑tested support level at $10.89. The company’s average analyst target is $24.33, well above its current range.